Hepatitis A News and Research

RSS

Hepatitis A (formerly known as ''infectious hepatitis'') is an acute infectious disease of the liver caused by the hepatitis A virus (HAV), which is most commonly transmitted by the fecal-oral route via contaminated food or drinking water.

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.

12 Aug 2011

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended June 30, 2011.

11 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

MAVS prion-like proteins are involved in innate immunity: Discovery

A person's ability to battle viruses at the cellular level remarkably resembles the way deadly infectious agents called prions misfold and cluster native proteins to cause disease, UT Southwestern Medical Center researchers report.

9 Aug 2011

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Thomas Jefferson University received a National Institutes of Health (NIH) $4.8 million grant to test a new rabies vaccine with the potential to cure the virus infection, even after it has made its way into a person's central nervous system (CNS). Today, if an unvaccinated person is infected with rabies and it spreads to the brain, there is little chance for survival.

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

GenMark Diagnostics second quarter revenues increase to $901,000

GenMark Diagnostics, Inc. today reported financial results for the second quarter ended June 30, 2011.

5 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Needle-free nanopatch vaccine delivery system

The needle-free nanopatch vaccine delivery system is coming soon after a consortium of investors put up $15 million for its development. The money will enable University of Queensland's Professor Mark Kendall to continue his work on the technology. It is described as the biggest breakthrough in vaccine delivery since the invention of the syringe more than 150 years ago.

3 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

ELPA, WHA announce educational program for hepatitis B patients

The European Liver Patients Association (ELPA) and the World Hepatitis Alliance (WHA), announced today on the 4th annual World Hepatitis Day that 'PATH B - "Patients and Professionals Acting Together for Hepatitis B" - My journey with chronic hepatitis B', a comprehensive educational resource designed to improve the lives of people living with chronic hepatitis B, is to be launched in August 2011.

29 Jul 2011

WHO marks first-ever World Hepatitis Day

The WHO on Thursday marked the first-ever World Hepatitis Day, recognizing a disease that affects nearly one of every three people in the world, the U.N. News Centre reports.

29 Jul 2011

Tips to make family vacations less hazardous for kids and parents

Family vacations live in infamy. Sometimes it's for the lasting memories of family bonding and new wonders experienced together, and sometimes for the horrors of just trying to get to a destination.

29 Jul 2011

Hepatitis on the rise

According to the World Health Organization (WHO), the battle is on to fight the rising numbers of hepatitis B cases. Medical experts are calling for global action to tackle the viruses that cause the liver disease hepatitis. The first worldwide estimates in drug users show 10 million have hepatitis C while 1.3 million have hepatitis B.

29 Jul 2011

ELPA, WHA to launch PATH B programme for patients with chronic hepatitis B

28 Jul 2011

OR models verify cost effectiveness of hepatitis B interventions

With hepatitis B infecting as many as 10% of people of Asian descent, operations researchers collaborated with a liver transplant surgeon to develop mathematical models that verified the cost effectiveness of hepatitis B interventions.

27 Jul 2011